Explore
This Special Issue focuses on the current state of pharmacogenomics (PGx) and the extensive translational process, including the identification of functionally important PGx variation; the characterization of PGx haplotypes and metabolizer statuses, their clinical interpretation, clinical decision support, and the incorporation of PGx into clinical care.
This book is included in DOAB.
Why read this book? Have your say.
You must be logged in to comment.
Rights Information
Are you the author or publisher of this work? If so, you can claim it as yours by registering as an Unglue.it rights holder.Downloads
This work has been downloaded 52 times via unglue.it ebook links.
- 52 - pdf (CC BY) at Unglue.it.
Keywords
- adaptation
- artificial intelligence
- best practice alerts (BPAs)
- Chronic Disease
- Chronic Kidney Disease
- clinical actionability
- clinical decision support (CDS)
- clinical translation
- community pharmacy
- CYP3A5
- electronic health records (EHR)
- Electronic Medical Record
- Genetic counseling
- genetic privacy
- genomic indicators
- genotype
- Human evolution
- implementation
- Machine learning
- medication management
- medicine
- n/a
- Other branches of medicine
- Pediatrics
- personalized medicine
- pharmaco-economics
- pharmacogenes
- Pharmacogenetics
- pharmacogenetics service
- pharmacogenomic
- pharmacogenomic testing
- Pharmacogenomics
- pharmacogenomics (PGx)
- Pharmacology
- Phenotype
- polymorphism
- polymorphisms
- polypharmacy
- pre-emptive
- precision medicine
- progression
- Qualitative
- return of results
- screening
- US Food and Drug Administration
Links
DOI: 10.3390/books978-3-0365-2834-2Editions